Investigation of Anti-Liver Cancer Activity of the Herbal Drug FDY003 Using Network Pharmacology. (9th September 2022)

• Record Type: Journal Article
• Authors: Lee, Ho-Sung; Lee, In-Hee; Park, Sang-In; Jung, Minho; Yang, Seung Gu; Kwon, Tae-Wook; Lee, Dae-Yeon
• Other Names: Saad Bashar Academic Editor.
• Is Part Of: Evidence-based complementary and alternative medicine. Volume 2022(2022)
• Publication Date: 2022-09-09
• Subjects: Alternative medicine -- Periodicals; 615.505
• DOI: 10.1155/2022/5765233
• Languages: English
• ISSNs: 1741-427X

Abstract

Abstract : Globally, liver cancer (LC) is the sixth-most frequently occurring and the second-most fatal malignancy, responsible for 0.83 million deaths annually. Although the application of herbal drugs in cancer therapies has increased, their anti-LC activity and relevant mechanisms have not been fully studied from a systems perspective. To address these issues, we conducted a system-perspective network pharmacological investigation into the activity and mechanisms underlying the action of the herbal drug. FDY003 reduced the viability of human LC treatment. FDY003 reduced the viability of human LC cells and elevated their chemosensitivity. There were a total of 16 potential bioactive chemical components in FDY003 and they had 91 corresponding targets responsible for the pathological processes in LC. These FDY003 targets were functionally involved in regulating the survival, proliferation, apoptosis, and cell cycle of LC cells. Additionally, we found that FDY003 may target key signaling cascades connected to diverse LC pathological mechanisms, namely, PI3K-Akt, focal adhesion, IL-17, FoxO, MAPK, and TNF pathways. Overall, this study contributed to integrative mechanistic insights into the anti-LC potential of FDY003.